Morgan Keegan Overweight on Edwards Lifesciences

Morgan Keegan is out with a research report on Edwards Lifesciences Corporation EW and it has an Overweight rating and a $91 price target on shares. In a note to clients, Morgan Keegan writes, "Investors are awaiting the approval of Edwards Sapien Valve, and we want to reiterate our conviction that the approval is imminent. Edwards is rated Outperform with a $91 Price Target." Shares of EW gained 60 cents on Friday to close at $76.06.